Victory Capital Sells Stake in Regeneron Pharmaceuticals

Institutional investor reduces holdings in biopharmaceutical company by over 50%

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. has reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.6% during the 3rd quarter, according to a recent 13F filing. The institutional investor now owns 82,386 shares of the biopharmaceutical company's stock, down from 170,278 shares previously.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotechnology industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. The reduction in ownership by a large institutional investor like Victory Capital could signal a shift in market sentiment or investment strategy regarding the company.

The details

According to the 13F filing, Victory Capital Management sold 87,892 shares of Regeneron Pharmaceuticals during the 3rd quarter. The firm's remaining holdings in the company are now valued at $46,323,000. Regeneron Pharmaceuticals has a market capitalization of over $80 billion and is considered a leader in the development of monoclonal antibody therapies.

  • Victory Capital Management filed its 13F report for the 3rd quarter of 2026.

The players

Victory Capital Management Inc.

An institutional investment management firm that has reduced its stake in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in ownership by Victory Capital Management could signal a broader shift in investor sentiment towards Regeneron Pharmaceuticals, though the reasons behind the firm's decision are not entirely clear from the available information. The company's continued success will likely depend on its ability to maintain its pipeline of innovative therapies and navigate the competitive biotechnology landscape.